Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KYMR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKymera Therapeutics amends bylaws to require federal courts for securities lawsuits
Filed March 27, 2026 · Period ending March 25, 2026 · ~1 min read
Key Changes
-
low
Board amended bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims, unless company consents to alternative venue in writing.
Item 5.03 verify on EDGAR → -
low
Change is procedural governance update responding to recent Delaware corporate law amendments, limiting where shareholders can file certain securities litigation.
8-K: Bylaw Amendment verify on EDGAR →
Summary
Kymera Therapeutics filed a routine corporate governance update on March 27, 2026, disclosing that its Board of Directors amended the company's bylaws on March 25. The amendment designates federal district courts as the exclusive forum for resolving lawsuits alleging violations of federal securities laws, unless Kymera consents in writing to an alternative venue.
This type of forum selection clause has become increasingly common among Delaware corporations following recent changes to state corporate law. For retail investors, this is a procedural change with minimal immediate impact. It does not affect the company's operations, financial position, or business strategy. The amendment simply determines where certain types of shareholder lawsuits must be filed.
Investors should note that this could make it slightly more difficult or expensive for shareholders to bring securities claims if they prefer state courts, though federal courts remain available. No follow-up action is required, but shareholders may want to review the full amended bylaws filed as Exhibit 3.1 if concerned about litigation rights.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Item 5.03 — Amendments to Articles of Incorporation or Bylaws filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.
The Board amended the company's bylaws to require that lawsuits alleging violations of federal securities laws must be filed in federal district courts, unless the company agrees otherwise in writing. This is a procedural governance change responding to recent Delaware corporate law amendments, limiting where shareholders can bring certain types of litigation.
Event · Item 9.01 — Financial Statements and Exhibits
Kymera Therapeutics filed Amendment No. 1 to its Second Amended and Restated Bylaws, a routine corporate governance update.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Amendment No. 1 to Second Amended and Restated Bylaws of Kymera Therapeutics, Inc.
The company filed an amendment to its corporate bylaws. Bylaws govern internal corporate procedures such as board meetings, officer duties, and shareholder rights. Without the exhibit text, the specific changes are unknown, but bylaw amendments are typically routine governance updates unless they materially alter shareholder rights or board structure.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify